G-Protein Coupled Receptors, Second Messengers — G-Protein Coupled Receptors and Second Messengers (cAMP/IP3) - Biochemistry

SECTION 1

Historical Context & Motivation

One of the most fundamental questions in cell biology has long been: how does a water-soluble hormone, unable to cross the lipid bilayer, trigger complex metabolic changes inside a cell? The discovery that cells possess dedicated transmembrane receptors capable of relaying extracellular messages to intracellular effectors transformed our understanding of physiology and pharmacology. At the center of this revolution are G-protein coupled receptors (GPCRs), the largest superfamily of membrane receptors in the human genome, and the second messenger molecules they activate — most notably cyclic AMP (cAMP) and inositol 1,4,5-trisphosphate (IP₃). The elucidation of these pathways earned multiple Nobel Prizes and remains a cornerstone of modern drug design, given that approximately 34% of all FDA-approved drugs target GPCRs.

1957 • Discovery of cAMP

Earl Sutherland identifies cyclic adenosine monophosphate (cAMP) as a heat-stable factor mediating the effects of epinephrine on glycogen phosphorylase in liver cells. He introduces the concept of 'second messengers,' earning the 1971 Nobel Prize in Physiology or Medicine.

1971 • G-Protein Signal Coupling

Martin Rodbell proposes that a transducer — later identified as a GTP-binding regulatory protein (G-protein) — couples hormone receptors to adenylyl cyclase. Alfred Gilman subsequently purifies the Gₛ protein. Both share the 1994 Nobel Prize.

1983 • IP₃ and Calcium Release

Michael Berridge and colleagues demonstrate that inositol 1,4,5-trisphosphate (IP₃) acts as a second messenger by triggering Ca²⁺ release from the endoplasmic reticulum, establishing the phospholipase C (PLC) signaling branch.

2007–2012 • GPCR Crystal Structures

Brian Kobilka and Robert Lefkowitz solve high-resolution crystal structures of the β₂-adrenergic receptor bound to its G-protein, revealing the molecular mechanism of activation. They share the 2012 Nobel Prize in Chemistry.

The central question these discoveries address is elegant in its simplicity: how does a single hormone molecule arriving at the cell surface generate a rapid, amplified, and precisely regulated intracellular response? The answer lies in a modular relay system — receptor, transducer, effector enzyme, and diffusible second messenger — whose architecture allows extraordinary signal amplification and exquisite pharmacological tunability.

SECTION 2

Core Principles & Definitions

GPCR signaling can be distilled into a set of foundational principles that govern how extracellular ligands produce intracellular effects. Understanding these principles provides a framework for predicting pathway behavior, interpreting pharmacological data, and appreciating why evolution has converged on this particular signaling architecture across virtually all eukaryotes.

Seven-Transmembrane Architecture

All GPCRs share a topology of seven α-helical transmembrane domains (TM1–TM7), an extracellular N-terminus, and an intracellular C-terminus. Ligand binding induces conformational changes in TM3, TM5, and TM6 that open a cytoplasmic cavity for G-protein coupling.

Heterotrimeric G-Protein Cycle

G-proteins consist of Gα, Gβ, and Gγ subunits. In the inactive state, Gα binds GDP. Receptor activation catalyzes GDP→GTP exchange on Gα, causing dissociation of Gα-GTP from Gβγ. Both species can activate downstream effectors until GTPase activity of Gα hydrolyzes GTP back to GDP, reassembling the heterotrimer.

Signal Amplification

Each activated receptor can sequentially activate many G-proteins; each Gα-GTP activates one effector enzyme that produces thousands of second messenger molecules. This catalytic cascade amplifies the original signal by orders of magnitude, enabling a few hormone molecules to elicit a robust cellular response.

Second Messengers: cAMP and IP₃/DAG

Second messengers are small, rapidly diffusible molecules generated (or released) in response to effector enzyme activation. cAMP is produced by adenylyl cyclase and activates PKA. IP₃ is generated by PLC-mediated cleavage of PIP₂ and releases ER Ca²⁺, while DAG activates protein kinase C (PKC).

Signal Termination

Signaling fidelity requires rapid termination. Key off-switches include GTPase activity of Gα (accelerated by RGS proteins), phosphodiesterases that degrade cAMP, receptor phosphorylation by GRKs leading to β-arrestin binding, and receptor internalization via clathrin-coated pits.

✦

KEY TAKEAWAY

Think of GPCR signaling like a relay race crossed with a megaphone. The hormone is the starting whistle — it never enters the cell. The receptor is the first runner who hands the baton (activation) to the G-protein, which hands it to an effector enzyme. But unlike a simple relay, each handoff is amplified: one enzyme produces thousands of cAMP or IP₃ molecules, like one person with a megaphone broadcasting to an entire stadium. Signal termination is equally essential — without the GTPase 'timer' and phosphodiesterase 'cleanup crew,' the cell would be locked in a permanent state of activation, much like a fire alarm that never shuts off.

SECTION 3

Visual Explanation: The GPCR–G-Protein–Effector Relay

This diagram illustrates the two major GPCR signaling branches side by side. On the left, ligand binding to a GPCR activates Gαs, which stimulates adenylyl cyclase to convert ATP into cAMP, ultimately activating PKA. On the right, Gαq activates PLC-β, which cleaves PIP₂ into IP₃ (triggering Ca²⁺ release from the ER) and DAG (activating PKC). Note the signal amplification at each stage: one ligand-receptor complex activates multiple G-proteins, and each effector enzyme generates thousands of second messenger molecules.

The diagram above captures the modular logic of GPCR signaling: the receptor, transducer (G-protein), effector enzyme, and second messenger are functionally separable components. This modularity means that evolution can 'mix and match' — different receptors can couple to the same G-protein class, or a single receptor can couple to multiple G-protein subtypes under different cellular contexts. The two pathways shown — the Gαs–adenylyl cyclase–cAMP–PKA axis and the Gαq–PLC-β–IP₃/DAG axis — represent the two most extensively characterized GPCR signaling cascades, though others (Gαi, Gα12/13) also exist.

SECTION 4

Molecular Mechanism: Step-by-Step Pathway Logic

The G-Protein Activation Cycle

The heart of GPCR signaling is the G-protein GTPase cycle, which acts as a molecular switch toggling between an inactive GDP-bound state and an active GTP-bound state. In the basal (resting) state, the heterotrimeric G-protein (Gαβγ) resides at the inner leaflet of the plasma membrane with GDP bound to the Gα subunit. Ligand binding induces a conformational change in the receptor that exposes an intracellular surface complementary to the Gα subunit. The activated receptor functions as a guanine nucleotide exchange factor (GEF), catalyzing the release of GDP and the binding of GTP — which is present in the cytosol at roughly 10× higher concentration than GDP. GTP binding triggers a conformational change in the switch I and switch II regions of Gα, causing the Gα-GTP complex to dissociate from Gβγ. Both Gα-GTP and the freed Gβγ dimer can now engage downstream effectors.

The cAMP Pathway (Gαs)

When the stimulatory G-protein subunit Gαs-GTP engages adenylyl cyclase (AC), the enzyme catalyzes the conversion of ATP to 3ʹ,5ʹ-cyclic AMP (cAMP) with release of pyrophosphate (PPᵢ). A single adenylyl cyclase molecule can produce hundreds of cAMP molecules per second, providing the first major amplification step. cAMP then allosterically activates protein kinase A (PKA) by binding to its two regulatory (R) subunits, releasing the two catalytic (C) subunits. Each free C subunit phosphorylates serine and threonine residues on target proteins, including CREB (cAMP response element-binding protein), which translocates to the nucleus to regulate gene expression, and metabolic enzymes such as glycogen phosphorylase kinase.

ADENYLYL CYCLASE REACTION

ATP → cAMP + PPᵢ

Catalyzed by adenylyl cyclase (AC); PPᵢ is subsequently hydrolyzed by pyrophosphatase, driving the reaction forward. The inhibitory subunit Gαi inhibits AC, providing an opposing regulatory input.

The IP₃/DAG Pathway (Gαq)

The Gαq-GTP subunit activates phospholipase C-β (PLC-β), which hydrolyzes the membrane phospholipid phosphatidylinositol 4,5-bisphosphate (PIP₂) into two second messengers: inositol 1,4,5-trisphosphate (IP₃) and diacylglycerol (DAG). IP₃, being water-soluble, diffuses through the cytoplasm and binds to IP₃ receptors on the endoplasmic reticulum membrane, which are ligand-gated Ca²⁺ channels. The resulting Ca²⁺ release raises cytoplasmic [Ca²⁺] from ~100 nM to ~1 μM, activating calmodulin-dependent kinases and other Ca²⁺-sensitive proteins. DAG remains membrane-associated and, together with Ca²⁺, activates protein kinase C (PKC), which phosphorylates a distinct set of substrates involved in cell growth, differentiation, and immune responses.

PLC-β REACTION

PIP₂ → IP₃ + DAG

PIP₂ = phosphatidylinositol 4,5-bisphosphate; IP₃ = inositol 1,4,5-trisphosphate (water-soluble); DAG = diacylglycerol (membrane-bound). This single cleavage event produces two functionally distinct second messengers.

SIGNAL TERMINATION — cAMP DEGRADATION

cAMP → 5ʹ-AMP (catalyzed by phosphodiesterase, PDE)

Phosphodiesterases hydrolyze the 3ʹ,5ʹ-phosphodiester bond in cAMP, converting it to the inactive 5ʹ-AMP. Caffeine and theophylline are competitive PDE inhibitors, which is why they prolong and enhance adrenergic signaling.

SECTION 5

Signal Amplification Cascade & G-Protein Diversity

A hallmark of GPCR signaling is the extraordinary degree of signal amplification achieved through a multi-tier catalytic cascade. Consider the epinephrine signaling cascade in liver cells. One molecule of epinephrine activates one β-adrenergic receptor, which in its active lifetime (~seconds) can sequentially activate ~100 Gαs proteins. Each Gαs-GTP activates one adenylyl cyclase molecule, which generates ~1,000 cAMP molecules before Gα-GTP is hydrolyzed. Each cAMP-activated PKA catalytic subunit phosphorylates ~10 substrate molecules. The result is a >10⁶-fold amplification: one hormone molecule can trigger the phosphorylation of millions of downstream targets within seconds.

The amplification cascade illustrates how a single epinephrine molecule binding to a β-adrenergic receptor results in the phosphorylation of approximately one million downstream targets. Each tier represents a catalytic step where one activated molecule generates many product molecules, creating an exponential amplification funnel.

Major Classes of Heterotrimeric G-Proteins

G-Protein Class	Primary Effector	Second Messenger Effect	Example Receptors
Gαs	Adenylyl cyclase (↑)	↑ cAMP → activates PKA	β-adrenergic, glucagon, ACTH
Gαi	Adenylyl cyclase (↓)	↓ cAMP → less PKA activity	α₂-adrenergic, muscarinic M₂, opioid
Gαq	PLC-β (↑)	↑ IP₃ + DAG → Ca²⁺ release + PKC	α₁-adrenergic, muscarinic M₁/M₃, angiotensin AT₁
Gα12/13	Rho GEFs	Activates Rho GTPase → cytoskeletal remodeling	Thrombin, LPA, thromboxane
Gβγ (released)	K⁺ channels, PI3Kγ, PLC-β	Diverse: K⁺ efflux, PIP₃ production	Varies by Gα partner

Summary of major heterotrimeric G-protein classes and their downstream effectors

SECTION 6

Worked Example: Tracing a Signal from Epinephrine to Gene Transcription

Let us trace the complete signaling pathway activated when epinephrine binds a β₂-adrenergic receptor on a hepatocyte, ultimately leading to CREB-dependent gene transcription. This example integrates every component of the GPCR→cAMP→PKA pathway and illustrates the sequential logic of signal transduction.

Epinephrine → β₂-Adrenergic Receptor → CREB Activation

1
Step 1 — Ligand Binding & Receptor Activation

Epinephrine, released from the adrenal medulla during the fight-or-flight response, reaches the hepatocyte surface and binds to the orthosteric binding site within the transmembrane helical bundle of the β₂-adrenergic receptor. This induces an outward movement of TM6 on the cytoplasmic face, creating a cavity that exposes residues critical for G-protein coupling.

GPCR adopts active conformation (R → R*)
2
Step 2 — G-Protein Activation (GEF Activity)

The activated receptor (R*) binds the heterotrimeric G-protein Gαsβγ at the cytoplasmic face. R* acts as a GEF for Gαs: it lowers the affinity of Gαs for GDP, allowing GDP to dissociate and GTP (which is ~10× more abundant in the cytosol) to bind. GTP binding induces conformational changes in the switch I and switch II regions of Gαs.

Gαs-GTP dissociates from Gβγ; both are now active
3
Step 3 — Effector Activation (Adenylyl Cyclase)

Gαs-GTP diffuses laterally along the membrane inner leaflet and binds to the C1 and C2 catalytic domains of adenylyl cyclase, stimulating cyclization of ATP to form cAMP. A single activated AC generates approximately 1,000 cAMP molecules per second.

ATP → cAMP + PPᵢ (massively amplified)
4
Step 4 — PKA Activation

cAMP molecules diffuse through the cytoplasm and bind cooperatively to two sites on each of the two regulatory (R) subunits of the tetrameric PKA holoenzyme (R₂C₂). Binding of four cAMP molecules total induces a conformational change that releases the two active catalytic (C) subunits.

R₂C₂ + 4 cAMP → R₂(cAMP)₄ + 2C (active)
5
Step 5 — CREB Phosphorylation & Gene Transcription

Free PKA catalytic subunits translocate to the nucleus, where they phosphorylate CREB at Ser-133. Phospho-CREB recruits the coactivator CBP/p300, which possesses histone acetyltransferase activity, facilitating transcription of CRE-containing target genes such as those encoding phosphoenolpyruvate carboxykinase (PEPCK) for gluconeogenesis.

CREB-P + CBP → transcription of metabolic genes (e.g., PEPCK)
6
Step 6 — Signal Termination

Termination occurs at multiple levels: (a) the intrinsic GTPase activity of Gαs hydrolyzes GTP → GDP (accelerated by RGS proteins), causing Gαs-GDP to reassociate with Gβγ; (b) phosphodiesterases (PDEs) degrade cAMP to 5ʹ-AMP; (c) GRK phosphorylates the receptor, promoting β-arrestin binding and clathrin-mediated endocytosis; (d) protein phosphatases dephosphorylate PKA substrates including CREB.

Signal reset: receptor internalized, cAMP degraded, G-protein reassembled

SECTION 7

Comparing the cAMP and IP₃/DAG Signaling Arms

While both pathways share the fundamental architecture of GPCR → G-protein → effector enzyme → second messenger → kinase, they differ in their chemical logic, temporal dynamics, and cellular outputs. Understanding these differences is essential for predicting the physiological consequences of receptor activation and for rational drug design targeting specific branches of signaling.

Feature	cAMP Pathway (Gαs)	IP₃/DAG Pathway (Gαq)
G-protein subtype	Gαs (stimulatory) or Gαi (inhibitory)	Gαq/11
Effector enzyme	Adenylyl cyclase	Phospholipase C-β (PLC-β)
Second messenger(s)	cAMP (soluble nucleotide)	IP₃ (soluble) + DAG (membrane-bound)
Source substrate	ATP (abundant cytosolic pool)	PIP₂ (minor membrane lipid; limited pool)
Downstream kinase	Protein kinase A (PKA)	Protein kinase C (PKC) + CaM kinases
Ion involvement	Indirect (PKA can phosphorylate ion channels)	Direct: IP₃ triggers ER Ca²⁺ release
Termination	PDE degrades cAMP → 5ʹ-AMP	IP₃ dephosphorylated; Ca²⁺ pumped back into ER by SERCA
Typical cellular outputs	Glycogenolysis, lipolysis, gene regulation (CREB), cardiac contractility	Smooth muscle contraction, platelet aggregation, secretion, immune activation
Pharmacological inhibitors	PDE inhibitors (caffeine, milrinone, sildenafil); forskolin activates AC directly	U73122 (PLC inhibitor); neomycin (binds PIP₂); 2-APB (IP₃R blocker)

Comparison of the two major GPCR second messenger pathways

✦

KEY TAKEAWAY

The cAMP and IP₃/DAG pathways are like two different broadcast networks running on the same cable infrastructure (the GPCR and G-protein framework). The cAMP channel specializes in metabolic and transcriptional programming — 'slow-burn' changes akin to adjusting a thermostat. The IP₃/Ca²⁺/DAG channel excels at rapid, spatially localized events — muscle contraction, secretion — more like flipping a light switch. A single cell can express receptors coupled to both pathways, allowing nuanced integration of multiple hormonal inputs into a unified physiological response.

SECTION 8

Connections to Advanced Signaling Concepts

The classical model of GPCR signaling — receptor activates G-protein, G-protein activates effector, effector generates second messenger — provides an essential foundation, but contemporary research has revealed layers of complexity that extend well beyond this linear relay. Understanding these advanced concepts is critical for graduate-level studies and for appreciating the pharmacological sophistication of modern GPCR-targeted therapeutics.

Classical Concept	Advanced Extension
One receptor → one G-protein → one effector	Biased agonism (functional selectivity): different ligands stabilize distinct receptor conformations that preferentially activate G-protein or β-arrestin pathways
β-arrestin = terminator of signaling	β-arrestin-mediated signaling: β-arrestins scaffold MAPK cascades (ERK1/2), Src kinases, and PI3K from endosomes, initiating a 'second wave' of signaling
GPCRs signal only from the plasma membrane	Endosomal signaling: internalized GPCR-β-arrestin-G-protein complexes ('megaplexes') continue to produce cAMP from endosomes, sustaining signals with distinct spatiotemporal profiles
GPCRs function as monomers	GPCR oligomerization: many GPCRs form homo- or heterodimers/oligomers (e.g., GABAB R1/R2 obligate heterodimer), altering ligand pharmacology and G-protein coupling
Cholera/pertussis toxin as research tools	Disease mechanisms: cholera toxin ADP-ribosylates Gαs (locks it in active, GTP-bound state → persistent cAMP → secretory diarrhea); pertussis toxin ADP-ribosylates Gαi (prevents receptor coupling → impaired inhibitory signaling); constitutively active GPCR mutations underlie McCune-Albright syndrome and some cancers

Classical vs. contemporary understanding of GPCR signaling

These advances have profound pharmacological implications. The concept of biased agonism, for example, has motivated the development of G-protein-biased opioid agonists (e.g., oliceridine) that aim to produce analgesia (via Gαi) with reduced respiratory depression and constipation (thought to be β-arrestin-mediated side effects, though this remains debated). Similarly, understanding allosteric modulators — drugs that bind GPCRs at sites distinct from the orthosteric pocket — allows fine-tuning of receptor activity rather than binary on/off switching, offering improved therapeutic windows for conditions from schizophrenia (muscarinic M₄ PAMs) to HIV (CCR5 negative allosteric modulators).

SECTION 9

Practice Problems

Question 1: CONCEPTUAL

Explain why a water-soluble hormone like glucagon cannot simply diffuse into a hepatocyte to regulate glycogen metabolism. How does the GPCR signaling architecture solve this problem, and what advantage does this indirect mechanism provide compared to direct intracellular action?

Show answer

Glucagon is a peptide hormone that is hydrophilic and cannot cross the hydrophobic lipid bilayer of the plasma membrane. The GPCR system solves this by transducing the extracellular signal across the membrane: glucagon binds the extracellular face of its GPCR, which undergoes a conformational change that activates Gαs on the cytoplasmic face, ultimately producing cAMP inside the cell. The key advantage of this indirect mechanism is signal amplification: one glucagon molecule generates thousands of cAMP molecules, enabling a robust metabolic response from a vanishingly small hormone concentration. Additionally, the multi-step relay provides multiple points of regulation — the cell can modulate signaling at the receptor level, at the G-protein level (via RGS proteins), or at the second messenger level (via phosphodiesterases), allowing precise control impossible with simple diffusion.

Question 2: BASIC CALCULATION

A single activated β-adrenergic receptor activates approximately 100 Gαs proteins during its active lifetime. Each Gαs-GTP activates one adenylyl cyclase molecule, which produces 1,000 cAMP molecules before GTP hydrolysis occurs. Four cAMP molecules are required to activate one PKA holoenzyme (releasing two catalytic subunits). How many active PKA catalytic subunits result from a single receptor activation event?

Show answer

Starting from one activated receptor: 1 receptor × 100 Gαs proteins = 100 activated adenylyl cyclase molecules. Each AC produces 1,000 cAMP, so total cAMP = 100 × 1,000 = 100,000 cAMP molecules. Since 4 cAMP molecules activate one PKA holoenzyme (R₂C₂), the number of activated holoenzymes = 100,000 ÷ 4 = 25,000. Each holoenzyme releases 2 catalytic subunits, so total active PKA C subunits = 25,000 × 2 = 50,000 active PKA catalytic subunits. This calculation illustrates the enormous amplification inherent in the cascade — from 1 hormone-receptor event to 50,000 active kinase molecules.

Question 3: INTERMEDIATE

A researcher treats cells with cholera toxin and observes sustained elevation of intracellular cAMP levels even after the hormone is washed away. Simultaneously, she adds the PDE inhibitor IBMX. Predict the combined effect on cAMP levels compared to either treatment alone, and explain the molecular basis of each perturbation.

Show answer

Cholera toxin catalyzes the ADP-ribosylation of Gαs, which inhibits its intrinsic GTPase activity. Consequently, Gαs remains locked in the GTP-bound (active) state, constitutively stimulating adenylyl cyclase and producing cAMP without receptor input. Normally, the cAMP produced would be degraded by phosphodiesterases (PDEs). IBMX is a non-selective PDE inhibitor that blocks the hydrolysis of cAMP to 5ʹ-AMP. The combined effect is synergistic: cholera toxin maximizes cAMP production (synthesis side), while IBMX minimizes cAMP degradation (breakdown side). Together, they produce cAMP levels substantially higher than either agent alone, because steady-state [cAMP] = rate of synthesis / rate of degradation; increasing the numerator and decreasing the denominator simultaneously causes a multiplicative increase.

Question 4: APPLIED

Sildenafil (Viagra) is a selective inhibitor of phosphodiesterase type 5 (PDE5), which is highly expressed in vascular smooth muscle. Nitric oxide (NO) activates soluble guanylyl cyclase to produce cGMP in these cells. Using your knowledge of second messenger logic, explain how sildenafil promotes vasodilation and why it is relatively tissue-selective despite cGMP being a ubiquitous second messenger.

Show answer

Nitric oxide released from endothelial cells diffuses into adjacent smooth muscle cells and activates soluble guanylyl cyclase, which converts GTP to cGMP. cGMP activates protein kinase G (PKG), which phosphorylates targets that lower intracellular Ca²⁺ and reduce myosin light chain phosphorylation, causing smooth muscle relaxation (vasodilation). Sildenafil inhibits PDE5, the enzyme that degrades cGMP to 5ʹ-GMP, thereby prolonging and amplifying the cGMP signal. Tissue selectivity arises because PDE5 is preferentially expressed in vascular smooth muscle of the corpus cavernosum, pulmonary vasculature, and retina, while other tissues express different PDE isoforms (e.g., PDE3 in cardiac muscle). This example illustrates a broader principle: second messenger signaling achieves specificity not only through receptor distribution but through the tissue-specific expression of degradative enzymes.

Question 5: CRITICAL THINKING

A pharmaceutical company is developing a 'biased agonist' for the μ-opioid receptor (a Gαi-coupled GPCR). The goal is to produce analgesia (mediated by Gαi-dependent inhibition of cAMP production and K⁺ channel opening) while minimizing respiratory depression (hypothesized to involve β-arrestin-2 recruitment). Design a screening strategy using cell-based assays that could distinguish G-protein-biased agonists from balanced agonists. What controls would you include, and what are two potential limitations of interpreting bias in vitro?

Show answer

A dual-assay screening strategy could measure (1) G-protein activation using a Gαi-sensitive cAMP inhibition assay (e.g., BRET-based cAMP sensor or GloSensor following forskolin stimulation), and (2) β-arrestin-2 recruitment using a reporter assay such as BRET/TANGO/PathHunter, which monitors receptor-arrestin proximity. For each candidate ligand, generate concentration-response curves for both readouts. A G-protein-biased agonist would show potent cAMP inhibition (low EC₅₀) but weak or absent β-arrestin recruitment (high EC₅₀ or reduced Emax). Controls should include: the full balanced agonist DAMGO as a reference, the endogenous ligand β-endorphin, naloxone (antagonist) as a negative control, and vehicle. Calculate bias factors using the operational model (ΔΔlog(τ/KA)). Two limitations: (1) System bias — overexpression of receptors or effectors in HEK293 cells can distort apparent bias relative to native neuronal tissue where expression levels differ. (2) Kinetic vs. thermodynamic bias — endpoint assays may miss transient G-protein or arrestin coupling events; real-time kinetic measurements (e.g., BRET) partially address this but still represent simplified systems compared to in vivo signaling networks with scaffolding proteins, receptor heterodimers, and compartmentalized signaling.

SUMMARY

Lesson Summary

Summary

G-protein coupled receptors (GPCRs) are seven-transmembrane receptors that transduce extracellular signals across the plasma membrane by activating intracellular heterotrimeric G-proteins (Gαβγ). Upon ligand binding, the receptor acts as a guanine nucleotide exchange factor (GEF), promoting GDP→GTP exchange on Gα. The activated Gα-GTP dissociates from Gβγ to engage downstream effector enzymes. In the cAMP pathway, Gαs stimulates adenylyl cyclase to convert ATP to cAMP, which activates protein kinase A (PKA) — leading to phosphorylation of metabolic enzymes and transcription factors like CREB. In the IP₃/DAG pathway, Gαq activates PLC-β, which cleaves PIP₂ into IP₃ (triggering ER Ca²⁺ release) and DAG (activating PKC).

The entire system is governed by signal amplification — a single hormone molecule can trigger the production of over 10⁶ phosphorylated targets — and signal termination mechanisms, including GTPase activity of Gα (accelerated by RGS proteins), cAMP degradation by phosphodiesterases, receptor desensitization by GRK/β-arrestin, and Ca²⁺ reuptake by SERCA. Approximately 34% of all approved drugs target GPCRs, underscoring the pathway's clinical importance. Advanced concepts — biased agonism, endosomal signaling, and GPCR oligomerization — continue to reshape our understanding and open new therapeutic avenues.